The itch severity item: Mediation modeling and measurement characteristics from a phase IIb trial of tasocitinib (CP-690,550), an oral Janus kinase inhibitor, in patients with plaque psoriasis

Authors
Category Primary study
JournalJournal of the American Academy of Dermatology
Year 2011
This article has no abstract
Epistemonikos ID: 81e84f83e966f4f31820ed280b646304b276e626
First added on: Feb 04, 2025